Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pinometostat + Azacitidine in 11q23-Rearranged AML
NCT03701295Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2020
- Primary completion
- Dec 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pinometostat in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Mar 2020; status: completed.
02
Drugs
pinometostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03701295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701295.